Real-world treatment satisfaction and quality of life (QoL) of patients treated with TG Therapeutics’ Briumvi (ublituximab) for relapsing multiple sclerosis (RMS) were shared from the BRILL study.
TG Therapeutics continues its efforts to differentiate itself from other anti-CD20 monoclonal antibodies (mAbs) with real-world evidence (RWE), which was presented on 27 June at the 12th Congress of the European Academy of Neurology (EAN) 2026.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
The BRILL study is a non-interventional, prospective, multicentre study currently ongoing in Germany, Austria, and Switzerland, with a planned sample size of 700 adults with active RMS.
In the study, patients attended regular clinical visits based on the intravenous (IV) infusion schedule of Briumvi. The schedule involves a second dose 15 days after the first dose, then subsequent doses every 24 weeks. The study enrolled a mix of treatment-naïve patients as well as those who received prior disease-modifying therapies, including other anti-CD20 mAbs.
The poster presentation at EAN 2026 shared treatment satisfaction, proportion of MS relapse episodes, and infusion-related reaction (IRR) rates at Week 24, where patients had received up to three doses of Briumvi. The mean treatment satisfaction of patients was assessed using the Treatment Satisfaction Questionnaire for Medication II (TSQM-II) domain scores out of 100 and based on 206 respondents. The scores were 68.0 for effectiveness, 89.7 for side effects, 82.6 for convenience, and 74.5 for global satisfaction. The mean quality of life as assessed by the mean EQ-5D-5L visual analogue scale (VAS) and total scores was high at baseline upon first dose, with minimal improvements after 24 weeks.
The interim analysis showed that the proportion of patients experiencing at least one MS relapse decreased by 95% in the first 24 weeks compared with the 12 months before Briumvi treatment. IRRs occurred most frequently at the start of treatment (in 24.5% of patients) and decreased with each treatment session to 8.4% at week 24. When compared with the data from the two pivotal trials of Briumvi (ULTIMATE I [NCT03277261] and ULTIMATE II [NCT03277248]), the frequency of IRRs was lower up to the data cut-off date of the BRILL study (43.4% in the ULTIMATE program versus 24.5% at the time of first infusion). Headaches and chills were among the most common IRRs in both the pivotal trials and the BRILL study.
Briumvi is the most recent anti-CD20 mAb to receive approval for the treatment of MS, in the US in 2022 and in the EU in 2024, following Roche/Genentech’s Ocrevus (ocrelizumab) and Novartis’s Kesimpta (ofatumumab), and competes within a drug class where therapies are differentiated by route of administration, dosing frequency, and treatment setting. Key opinion leaders (KOLs) previously interviewed by GlobalData viewed anti-CD20 mAbs as broadly comparable on disease control and reduction of annual relapse rates (ARR) in patients with RMS.
But a key gap across the anti-CD20 mAbs in the MS landscape is the lack of robust, head-to-head real-world comparisons incorporating standardised patient-reported outcomes. While individual studies suggest a generally high treatment satisfaction across the mAbs, the heterogeneity of the studies limits meaningful cross-trial benchmarking. A direct comparative real-world study including treatment discontinuation and persistence rates would strengthen differentiation between the therapies and better inform prescribing decisions in an increasingly crowded anti-CD20 mAb market where patient-centred outcomes are gaining greater strategic importance.
For Briumvi, a later entrant into a competitive anti-CD20 mAb MS market, real-world data on parameters such as patient treatment satisfaction and QoL are strategically valuable because differentiation on efficacy alone is becoming more challenging. Patient-centred outcomes, including treatment convenience, satisfaction, quality of life, and overall treatment burden, are becoming more influential in treatment selection. The final BRILL findings could help build a differentiated value proposition for Briumvi centred on the patient experience, an area of growing importance as competition within the anti-CD20 mAbs intensifies.
Across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), GlobalData expects the anti-CD20 mAbs, including biosimilars, to generate sales of $8.1bn by 2034.
GlobalData is the parent company of Clinical Trials Arena.
